Adial Pharmaceuticals to Present at 23rd Annual ICR Conference

Rhea-AI Summary

Adial Pharmaceuticals will present an overview at the 23rd Annual ICR Conference on January 14, 2021, from 3:15 PM to 3:55 PM ET. CEO William Stilley will lead the presentation, which will focus on the company's advancements in treatments for addictions, particularly the investigational drug AD04 aimed at treating Alcohol Use Disorder (AUD). This drug is currently in a pivotal Phase 3 trial. A live webcast will be available on Adial's website, with replays accessible for 90 days.

CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals has been invited to present a Company overview at the 23rd Annual ICR Conference on Thursday, January 14, 2021 at 3:15pm-3:55pm Eastern Time.

A live webcast of the Company's presentation will be available on the Investors section of the Company's website (https://www.adialpharma.com/). A webcast replay will be accessible for 90 days following the live presentation.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ Phase 3 Pivotal Clinical Trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adialpharma.com.

Contact:

Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: adil@crescendo-ir.com

SOURCE: Adial Pharmaceutical, Inc.

View source version on accesswire.com:
https://www.accesswire.com/623791/Adial-Pharmaceuticals-to-Present-at-23rd-Annual-ICR-Conference

FAQ

What is the date and time of Adial Pharmaceuticals' presentation at the ICR Conference?

Adial Pharmaceuticals will present at the ICR Conference on January 14, 2021, from 3:15 PM to 3:55 PM Eastern Time.

How can I watch the Adial Pharmaceuticals presentation?

The presentation can be viewed live via webcast on the Investors section of Adial Pharmaceuticals' website.

What is the main focus of Adial Pharmaceuticals' presentation?

The presentation will focus on Adial's development of treatments for addictions, especially the drug AD04 for Alcohol Use Disorder.

What is the status of the AD04 clinical trial?

AD04 is currently being investigated in the ONWARD Phase 3 Pivotal Clinical Trial for its potential to treat Alcohol Use Disorder.

How is AD04 expected to help with addictions beyond Alcohol Use Disorder?

AD04 is also believed to have potential applications in treating Opioid Use Disorder, gambling, and obesity.